UPDATE: Jefferies Increases PT on ZIOPHARM to $7

Jefferies reiterates a Buy rating on ZIOPHARM Oncology ZIOP and increases its price target from $6 to $7. Jefferies notes, “At its R&D Day (6/19/12), ZIOP highlighted (1) palifosfamide in STS and SCLC; (2) PFS as a validated endpoint for FDA full approval: & (3) early IL-12 DNA therapeutics. ZIOP expects Ph3 palifosfamide PFS data in 1st-line sarcoma by YE12, with Ph3 SCLC data in ~2014-2015. On recent FDA full approval of Votrient in Tx-experienced sarcoma, it notes FDA's clear policy shift in favor of PFS benefits for full approvability.” ZIOP closed at $5.89 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorNewsPrice TargetEventsAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!